Bayer AG
XETRA:BAYN
Intrinsic Value
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. [ Read More ]
The intrinsic value of one
BAYN
stock under the Base Case scenario is
93.82
EUR.
Compared to the current market price of 52.83 EUR,
Bayer AG
is
Undervalued by 44%.
Fundamental Analysis
Balance Sheet Decomposition
Bayer AG
| Current Assets | 39.6B |
| Cash & Short-Term Investments | 8B |
| Receivables | 18.1B |
| Other Current Assets | 13.5B |
| Non-Current Assets | 85.4B |
| Long-Term Investments | 2.8B |
| PP&E | 13.3B |
| Intangibles | 62.6B |
| Other Non-Current Assets | 6.7B |
| Current Liabilities | 34.4B |
| Accounts Payable | 6.3B |
| Other Current Liabilities | 28.1B |
| Non-Current Liabilities | 49.8B |
| Long-Term Debt | 33.6B |
| Other Non-Current Liabilities | 16.2B |
BAYN Profitability Score
Profitability Due Diligence
Bayer AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Bayer AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
BAYN Solvency Score
Solvency Due Diligence
Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAYN Price Targets Summary
Bayer AG
According to Wall Street analysts, the average 1-year price target for
BAYN
is 76.06 EUR
with a low forecast of 57.57 EUR and a high forecast of 105 EUR.
Shareholder Return
BAYN Return Decomposition
Main factors of price return
Market capitalization of
BAYN
shares
decreased
by
24.21%
over the past 5 years.
The primary factor behind the change was
a decrease
in net margin from
19.2%
to
6%, leading to a
drop
in the market capitalization of Bayer AG by 101.43%.
Market capitalization of
BAYN
shares
decreased
by
24.21%
over the past 5 years.
The primary factor behind the change was
a decrease
in net margin from
19.2%
to
6%, leading to a
drop
in the market capitalization of Bayer AG by 101.43%.
BAYN Price
Bayer AG
| Average Annual Return | -10.54% |
| Standard Deviation of Annual Returns | 29.98% |
| Max Drawdown | -56% |
| Market Capitalization | 52B EUR |
| Shares Outstanding | 982 420 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Bayer AG
Country
Industry
Market Cap
Dividend Yield
Description
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
Contact
IPO
Employees
Officers
The intrinsic value of one
BAYN
stock under the Base Case scenario is
93.82
EUR.
Compared to the current market price of 52.83 EUR,
Bayer AG
is
Undervalued by 44%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
